Decreases in the Disease Activity Score in @ joints using the C-reactive protein level ( DAS@-CRP ) , Clinical Disease Activity Index ( CDAI ) , and CRP level from baseline were observed at week @ in the ixekizumab groups in both populations ( P < @ versus placebo ) .